Award
National Cancer Institute 5R37CA246239-07
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$351,924.00
Ceiling
$351,924.00
Awarded
January 29, 2026
Identifier
5R37CA246239-07
Award for research on enhancing checkpoint blockade immunotherapy through in situ vaccination to stimulate tumor-reactive T cells, funded by the National Cancer Institute.
Description
This project involves immunology studies related to checkpoint blockade immunotherapy, in situ vaccination, and tumor-specific T cell responses. It is funded by the NIH/NCI and involves clinical and preclinical research.